Essential Pharma
Manufacturing · United Kingdom · 51-200 Employees
View Company Info for Free
Overview
Headquarters
8a Crabtree Rd, Thorpe Ward, Surrey, TW2...Phone Number
+44 1784477167Website
www.essentialpharmagroup.comRevenue
$35.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Essential Pharma
Essential Pharma is a specialist pharmaceutical company dedicated to ensuring access to essential medicines, particularly for small, underserved, or rare disease populations. The company focuses on developing and delivering high-quality therapies, including those at risk of discontinuation, across various therapeutic areas such as rare diseases, CNS, ophthalmology, and gastroenterology. With a growing portfolio of products available in approximately 70 countries, Essential Pharma aims to address significant unmet medical needs. Their commitment to corporate responsibility and innovation drives their mission to transform lives through reliable healthcare solutions.Explore more
Essential Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Essential Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Essential Pharma is spiking on competitors!
Product Launch: Get notified when Essential Pharma launches new products
Funding: Get notified immidiatlly once Essential Pharma has new funding data
Check if Essential Pharma has recently received funding, and reach out quickly before it becomes old news!
Essential Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Essential Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Essential Pharma had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Essential Pharma
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Essential Pharma
Find 3 more new buyers
Compare Similar Companies to Essential Pharma
Compare insights from companies similar to Essential Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Essential Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Essential Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Essential Pharma.
Essential Pharma financials insights
Gather financial insights about Essential Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Unspecified
$936M
Essential Pharma Tech Stack
A closer look at the technologies used by Essential Pharma
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
Essential Pharma News & Media
Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma
UK – 14 April 2026 – Renaissance Pharma Limited, an Essential Pharma company focused on development stage assets, today announces that the US Food and Drug Administration (FDA) has granted Fast Track Designation for Daretabart (hu1418K322A), a novel anti-GD2 monoclonal antibody in development for the treatment of high-risk neuroblastoma (HRNB), a rare paediatric cancer. The designation recognises the significant unmet medical need in HRNB and will support more frequent interactions with the FDAEssential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertension
Egham, UK – 17 February 2026 – Essential Pharma (“Essential” or “the Company”), a global specialty pharmaceutical company, today announces the acquisition of Ventavis® (iloprost trometamol) from Bayer AG, including rights to the accompanying Breelib® nebuliser delivery technology.UK: Essential Pharma appoints CFO and CTO to accelerate growth - Investors in Healthcare
Essential Pharma appoints CFO and CTO to accelerate growthEssential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Essential Pharma
Sign Up For FreeTo access detailed company insights
Essential Pharma is a specialist pharmaceutical company dedicated to ensuring access to essential medicines, particularly for small, underserved, or rare disease populations. The company focuses on developing and delivering high-quality therapies, including those at risk of discontinuation, across various therapeutic areas such as rare diseases, CN... Read More
